Background Clinical samples were distributed on 10 occasions to six UK laboratories that perform urinary steroid profile analysis. Urine samples were from normal adult men and women, normal children and neonates. Samples from patients with Cushing's syndrome, virilization, adrenarche, obesity and congenital adrenal hyperplasia (21 and 17-hydroxylase defects) were also used for evaluation.
Introduction
As part of endocrine investigations, steroids in biological £uids are analysed qualitatively and quantitatively. Immunoassay is widely used and quality assessment schemes are well established, e.g. United Kingdom National External Quality Assessment Service (UK NEQAS). Chromatographic methods for steroid analysis are also used in specialized centres. Similar analytical work is used for the detection of other inborn errors of metabolism, such as organic acidurias, and an external quality assessment scheme for these analytes has been in operation for many years. Measurement of the major steroid metabolites in urine is achieved after extraction, puri¢cation, derivatization, chromatographic separation, and ¢nally detection by £ame ionization or mass spectrometry. This technique allows comprehensive characterization of steroid excretion patterns as well as determination of precursor:product ratios, which can provide critical diagnostic information.
In many laboratories steroid pro¢le analysis is performed using capillary column gas chromatography, often integrated with mass spectrometry. Some laboratories use pattern recognition and retention characteristics to interpret data.
Many disorders of steroid metabolism present in the newborn period, a time when adrenal cortical function and steroid metabolism is complicated. Di⁄culties arise in the use of immunoassays because the methodology has often only been characterized for samples from adult patients, in whom the general mixture of circulating steroid hormones is well de¢ned. There are problems in applying immunoassay techniques in neonates, and specialized endocrine laboratories are frequently consulted when equivocal results have been obtained with samples from newborn infants. 1 In our laboratory, the paediatricians initiate the majority of requests for urine steroid pro¢les. This has imposed immense problems for the relevant quality assurance schemes, e.g. blood 17-hydroxyprogesterone, because it has been di⁄cult to obtain su⁄cient paediatric material for inclusion. Some specialist laboratories now o¡er genetic investigations 2 for steroidogenic enzyme defects once the defect has been characterized by biochemical techniques. However, other specialist endocrine laboratories may have a di¡erent referral pattern, possibly of a more adult nature (Cushing's syndrome, polycystic ovarian syndrome and hypertension).
The urine steroid pro¢le has an important role because each peak can be assigned to a particular steroid, and the overall pro¢le characteristically re£ects where the metabolic block is located. Another important attribute of urine steroid pro¢ling is that urine excretion rates of androgens and cortisol metabolites approach production rates. This means that in a 24-h urine collection adrenal activity can be integrated. By comparison with normal data both adrenal suppression and over-production can be diagnosed.
There are currently six laboratories in the UK o¡ering urine steroid pro¢les. This report summarizes the performance of all six laboratories in this UK NEQAS pilot scheme to evaluate both analytical and interpretational competence.
Methods

Study design
Urine samples from clinical investigations were heattreated to destroy human immunode¢ciency virus and had gentamicin added as preservative. The urine samples were then stored frozen in 10-mL aliquots. The participants received four frozen aliquots of urine every 3 months and they were asked to analyse them and report the results in their usual way, as if the samples were part of their usual workload. A chromatogram was also requested for each sample.
Samples distributed
A total of 16 samples representative of the clinical workload were distributed. Box 1 shows the range of clinical samples distributed. Some samples were distributed on more than one occasion.
On registration with the pilot quality assurance scheme, all participants were asked to complete a questionnaire about sample requirements and methodology used.
Results
The participating laboratories returned their results in their usual format of reporting. Both qualitative and quantitative summaries were constructed.
Quantitative summaries
For many samples, particularly when steroid outputs were in or near the expected reference ranges, there was very good agreement in the results despite the complexity of the analysis. However, results agreed less well when steroid outputs were high. Quantitative results showed less variation within most laboratories than between laboratories. Tables 1 and 2 show qualitative summaries of the above data. Di¡erences in the quality of advice given could be attributed to the availability of appropriate reference ranges, experience of those interpreting urinary steroid pro¢les and awareness of scienti¢c literature. In general, the interpretation of results was not compromised by inaccuracy of interpretation, except in one case. This was in a sample from a child with an androgen-secreting tumour [dehydroepiandrosterone sulphate (DHAS)], for whom the diagnostic preference was towards a genetic defect of 3b-hydroxysteroid dehydrogenase de¢ciency (see Table 3 ).
Qualitative summaries
Discussion
The analysis of urinary steroids is achieved by a complex procedure consisting of extraction, separation of conjugates (neonatal), hydrolysis, formation of derivatives, and analysis by gas chromatography (GC) or gas chromatography with mass spectrometry (GCMS). Urine steroid pro¢ling is usually provided by specialist endocrine laboratories. Six laboratories took part in this UK-wide EQA pilot urinary steroid pro¢ling scheme and 16 samples were analysed in total. The majority of participants used solid-phase extraction (Sep-Pak) and hydrolysis with enzymes from Helix pomatia in acetate bu¡er. Duration of hydrolysis at 37 8C varied from 18 to 72 h, with a shorter duration for newborns if the results were required urgently. Most participants used methyloxime/trimethylsilyl ether derivatives (MO TMS) followed by either a solvent or lipidex clean-up stage before analysis by GC or GCMS. One participant utilized 17-oxogenic methodology 3 before derivatization and GC analysis.
Throughout this pilot scheme there was very good agreement in results returned from participating laboratories. However, this agreement became less prominent when steroid output was elevated. This was A normal profile. This eliminates Cushing's syndrome and all inborn errors of steroid metabolism associated with hypertension. Conn's adenoma is usually accompanied by a relative increase of corticosterone metabolites, especially tetrahydro-11-dehydrocorticosterone, and this is not evident. There is thus no positive evidence for Conn's, but neither is it eliminated. 4 The profile is that of a normal male. There is no evidence of hyperaldosteronism nor of Cushing's syndrome, which can cause hypertension. There is also no evidence of any of those rare enzyme deficiencies which can be investigated by a urinary steroid profile and which can cause hypertension (11b-hydroxylase, 17a-hydroxylase and 11b-hydroxysteroid dehydrogenase type 2 deficiency). 5
Essentially a normal steroid profile. As this method does not assess aldosterone metabolites or separated out THF from THE, we would recommend investigating the patient's renin-aldosterone axis. If the renin was suppressed without an elevated aldosterone, the possibility of 11b-hydroxysteroid dehydrogenase deficiency would need to be considered. This would require confirmation with a high-resolution steroid profile. 6
Normal output of cortisol metabolites. No mineralocorticoids (DOC, corticosterone, 18-hydroxycortisol) in excess. Reference range normal child 2-6 years (n ¼ 15). Partial 21-hydroxylase deficiency is indicated by an excess of 17hydroxyprogesterone metabolites in a typical pattern, together with cortisol metabolites. There is a paradoxical increase in the latter, a frequent finding in this disorder. Androgen metabolites, including DHA and its metabolites, are at markedly increased levels. 4
Reference data child 2-6 years (n ¼ 15). All urinary steroids are high for a child of this age; androgens in particular are very high as are metabolites of 17-hydroxyprogesterone (pregnanetriol, 11-oxo-pregnanetriol and 17-hydroxypregnanolone). The profile is typical of 21-hydroxylase deficiency. The ratios of 17-hydroxyprogesterone to cortisol metabolites is higher than those reported in the non-classical/late-onset form of the condition but rather low for the classical condition. There were none of the indicators of other enzyme deficiencies which can cause precocious puberty, nor any indicators of adrenal tumour, which are sometimes seen in the steroid profile. 5
The most prominent abnormality is a well raised pregnanetriol (or THS) level for this age. Although the cortisol metabolites are within normal limits, there is a relative block in the cortisol biosynthetic pathway consistent with CAH. An adrenal tumour cannot be excluded. The androgen metabolites are also well raised and would account for the virilization. If CAH, then 21-hydroxylase deficiency is the most likely, although rare forms of CAH cannot be excluded by our method.
Recommend that the patient is further assessed by taking blood for 17-OH-P, androstenedione, DHAS and testosterone on an early morning sample. Assessing urine and serum steroids after dexamethasone may be necessary. 6
Reference ranges for normal boys aged 6 years. High excretion rates of androgens and metabolites of 17hydroxyprogesterone and 21-deoxycortisol. Normal output of cortisol metabolites. This result is consistent with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. with an appropriate internal standard to correct for procedural losses. Production of standard curves is limited to the availability of the pure steroids.
. Participants using mass spectrometry used single ion monitoring (SIM). Ion currents of preselected intense masses characteristic of the compound of interest are monitored. The height of the selected ion peak is used rather than the height of the total ion peak.
Depending on the type of column used and GC run conditions, there may be some degree of non-linearity of the response, leading to greater imprecision at elevated levels of steroids. Some steroids do not meet ideal peak heights and appropriate correction factors are employed. It is advisable to check correction factors used periodically if using peak height responses. Another factor to take into consideration is the coelution of steroids in the gas chromatogram. An example of this is the co-elution of 11b-hydroxyandrosterone and 17-hydroxypregnanolone, which could lead to an over-estimation of the 17-hydroxypregnanolone concentration. These two steroids can be resolved by preparing the BO TMS derivatives. In untreated 21-hydroxylase de¢ciency, 11b-hydroxyandrosterone would be absent, but it would be present if the patient was treated with hydrocortisone. Alternatively, these two steroids could be quanti¢ed by mass spectrometry using SIM.
Other methodological factors, such as incomplete hydrolysis of conjugates and incomplete derivative formation, will also directly in£uence steroid excre-tion rates. In an attempt to address these inconsistencies, it is planned to distribute spiked samples to evaluate recoveries and add steroid conjugates to evaluate e⁄ciency of hydrolysis.
Along with each quantitative report, participants were asked to interpret the urine steroid pro¢le. Brief summaries of clinical details were provided with each sample. The interpretative comments were in general short and precise, with a clear explanation of the ¢ndings. In some cases, there were recommendations for any con¢rmatory tests. It seems helpful to ascribe steroid metabolites to their circulating hormones.
Most laboratories constructed their own reference ranges from local populations. These reference ranges show variability between laboratories. The strength of the advice given re£ected the reference ranges used. Adult reference intervals are relatively easy to construct, whereas those for neonates and children are more di⁄cult because reference ranges change with age. Considerable experience is required to interpret urine steroid pro¢les as they are extremely complex. Furthermore, it is vital that current awareness of scienti¢c literature is kept up-to-date.
The one example in which interpretation di¡ered was in a sample from a 4-year-old girl with a DHASsecreting tumour. The clinical information provided with the sample was 'virilization'. Three laboratories reported high concentrations of DHA, one reported elevated androgens and two did not comment. Only two laboratories reported low or subnormal cortisol concentrations. Two laboratories suggested the most likely metabolic defect was 3b-hydroxysteroid dehydrogenase de¢ciency (3b-HSD). One said 3b-HSD de¢ciency was unlikely and the other three laboratories did not comment. Three laboratories thought the diagnosis of a tumour possible; one of these laboratories also suggested 3b-HSD de¢ciency. Only two laboratories requested a repeat sample. Two laboratories advocated a range of further tests. These included measurement of adrenocorticotrophic hormone (ACTH), 17-hydroxyprogesterone, 17hydroxypregnanolone, DHAS, cortisol and a dexamethasone suppression test. If this patient had 3b-HSD de¢ciency there would be subnormal concentrations of cortisol metabolites present and increases in metabolites of pregnenolone, 17-hydroxypregnenolone and DHA. Adrenal tumours secreting DHA may present with grossly elevated concentrations of DHA and its metabolites, such as16hydroxy-DHA. Cortisol concentration is usually low to normal in DHAS-secreting tumours. Both 3b-HSD de¢ciency and DHA-secreting tumours can present with virilization of a female, but the enzyme defect would additionally lead to adrenal failure and saltlosing problems, especially in severely a¡ected patients in early infancy. Survival to 4 years without treatment would be unusual. By contrast, milder or late-onset variants have also been described 4 in which patients do not present until late childhood or adolescence. Only one laboratory suggested performing a dexamethasone suppression test to distinguish between 3b-HSD de¢ciency and adrenal tumour. Given the discrepancy of interpretation, the need for continued assessment of interpretational comments appended to urinary steroid pro¢les is highlighted. This can only improve the overall quality of service provided by specialist endocrine laboratories o¡ering urine steroid pro¢le analysis.
Conclusion
This pilot UK-NEQAS urinary steroid pro¢ling scheme has clearly identi¢ed the requirement for external quality assessment. Positive feedback has been received from all participants and external assessment by the steering committee.
It is now hoped to start the scheme again in 2005, possibly in collaboration with the European Research Network for the Evaluation and Improvement of Screening, Diagnosis and Treatment of Inherited Disorders of Metabolism, on a Europe-wide basis, and then eventually 'go global'. Further information on the pilot scheme not included in this short report can be obtained from the author.
